Dexcom (DXCM) Q1 2026 earnings review
Massive Margin Expansion Steals the Show
Dexcom delivered a flawless operational quarter, proving its recovery from early 2025 supply chain issues is complete. While revenue grew a solid 15% YoY to $1.19B, the real story is the bottom line: Non-GAAP operating income skyrocketed 85% YoY as margins expanded dramatically. Management is passing this efficiency through to investors by raising FY26 margin guidance while prudently maintaining the revenue outlook. The gap between U.S. and International growth is widening, highlighting international expansion as the primary growth engine for the near future.
🐂 Bull Case
Gross and operating margins have fully reversed the weakness seen in early 2025. Non-GAAP operating margin expanded 840 basis points YoY to 22.2%, triggering a full-year guidance raise.
International revenue accelerated, growing 26% reported (17% organic) and outpacing U.S. growth. This validates management's strategy to eventually make the international business larger than the core U.S. market.
🐻 Bear Case
Management reiterated FY26 revenue growth guidance of 11-13%. Following a 15% print in Q1, this implies a deceleration to the low double digits for the remainder of the year.
Despite current margin highs, the upcoming launch of the Ireland manufacturing facility in Q4 2026 will create significant fixed cost drag, temporarily depressing gross margins at year-end.
⚖️ Verdict: 🟢
Bullish. The top-line growth is highly stable, but the bottom-line execution is spectacular. Dexcom has structurally improved its profitability profile, though investors should brace for anticipated factory start-up costs later this year.
Key Themes
G7 15-Day Launch Catalyst
The G7 15-Day CGM system has expanded across all U.S. channels. This product is a crucial driver for both sales growth and margin improvement. By extending wear time, it provides a superior customer experience (improving retention) and lowers the per-day cost of goods sold, directly contributing to the 600 bps YoY gross margin expansion.
International Operations Accelerating
The gap between U.S. and International performance is widening favorably for global reach. International revenue grew 26% on a reported basis (17% organic) to $359.6M. With a tiered product portfolio (Dexcom One+, G7, Stelo) winning tenders in Europe, the international segment is the definitive growth leader, offsetting slightly moderating U.S. growth (+11%).
Type 2 Non-Insulin CMS Coverage Unlocking
Dexcom's largest future growth driver remains contingent on the Type 2 non-insulin population. The company showcased highly favorable one-year registry data at ATTD 2026 demonstrating significant A1C improvement for this cohort. A pending Medicare (CMS) coverage decision could open access to nearly 12 million new potential users, driving structural volume growth.
Ireland Facility Start-up Will Contradict Margin Narrative
While Dexcom is currently printing massive YoY margin expansion, a significant data point contradicts this extending indefinitely. Management has previously guided that Q4 2026 will bear heavy fixed-cost burdens from turning on the new Ireland manufacturing facility. These costs run through OpEx and COGS, meaning the current 63.5% gross margin will likely compress in Q4 despite strong volumes.
U.S. Revenue Decelerating
U.S. revenue grew 11% YoY to $832.3M. While solid, this is a deceleration from the 15% U.S. growth rate reported in Q1 2025. Given the U.S. makes up 70% of total revenue, sustaining total company double-digit growth requires the U.S. market to stabilize and not slip into single-digits.
Software and Ecosystem Sticky Features
Dexcom introduced enhanced Smart Meal Logging features to the Stelo platform. This shift from pure hardware to integrated software/AI-driven insights is critical for retaining cash-pay (OTC) customers and differentiating from competitors who compete heavily on price.
Other KPIs
Accelerating. Non-GAAP EPS surged 75% YoY, up from $0.32 in Q1 25. This heavily outpaced revenue growth, demonstrating exceptional flow-through to the bottom line.
Stable and highly flexible. Up from $1.99 billion at the end of FY25. The revolving credit facility remains undrawn, leaving the company heavily capitalized to handle the upcoming Ireland facility scale-up and potential share repurchases.
Guidance
Stable. The reiterated guidance implies 11-13% YoY growth. Since Q1 came in at 15% growth, the math requires a deceleration in the remaining three quarters. Management may be leaving room for outperformance or bracing for base effects.
Accelerating. Management explicitly raised this from the prior ~22-23% expectation. With Q1 coming in at 22.2%, the guidance implies further operating leverage as the year progresses, prior to the Q4 factory launch.
Accelerating. Raised from previous 30-31% guidance, cementing the narrative that supply chain and freight issues from early 2025 have been permanently engineered out of the cost structure.
Key Questions
Ireland Facility Margin Drag
With the guidance raise for full-year operating margins, how material will the Q4 margin compression be from the Ireland facility launch, and when will that facility reach breakeven utilization?
U.S. Market Dynamics
U.S. growth decelerated to 11% this quarter. How much of this is driven by price/mix changes in the pharmacy channel versus competitive pressure, and what gets U.S. growth reaccelerating?
Stelo Cannibalization vs Expansion
With the integration of Smart Meal Logging into Stelo, are you seeing any cannibalization of the lower-acuity G7 user base, or is Stelo remaining purely an on-ramp for non-covered patients?
CMS Type 2 Non-Insulin Timeline
Given the presentation of one-year registry data at ATTD, what is the latest read on the timing of a CMS coverage determination for the 12 million Type 2 non-insulin lives?